Nintedanib
- BNF:
- 8.1.5
- Status:
- Red
- Decision Date:
- March 2015
Comments
RED:
- NICE TA347: nintedanib for previously treated locally advanced, metastatic or locally recurrent non-small cell lung cancer. (Decision date - August 2015)
- NICE TA379: nintedanib for treating idiopathic pulmonary fibrosis. (Decision date - February 2016)
- NICE TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases. (Decision date - December 2021)
- NICE TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (Decison date - March 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again